Biomea Fusion, Inc. (BMEA): Insider Trading, Congress Trades & Research | Tormere
BMEA
$0.57-3.44%
Biomea Fusion, Inc.
Market Cap
$41M
Live price × SEC shares (Jul 31, 2026)
Sector
Health Care
Industry
Biotechnology
Beta (raw)
-0.17
60mo monthly vs SPY
P/E (TTM)
N/M
TTM to Jun 2026 · negative earnings
P/S (TTM)
—
Mkt cap / TTM revenue
P/B
3.4
Mkt cap / shareholders' equity
EV/EBITDA (TTM)
—
EV / TTM EBITDA
Loading…
Financial Statements
USD thousands
Q3 FY2025
Sep 30, 2025
Q4 FY2025
Dec 31, 2025
Q1 FY2026
Mar 31, 2026
Q2 FY2026
Jun 30, 2026
TTM
Jun 30, 2026
Research & development
14,401
8,115
9,120
9,142
40,778
Total operating expenses
20,805
11,719
12,774
12,766
58,064
Operating income
(20,805)
(11,719)
(12,774)
(12,766)
(58,064)
Net income
(16,407)
4,612
(12,415)
(8,328)
(32,538)
EPS (basic) ($)
(0.27)
(0.17)
(0.12)
—
EPS (diluted) ($)
(0.27)
(0.17)
(0.12)
—
Weighted avg. shares (basic)
59,848
72,299
72,360
Weighted avg. shares (diluted)
59,848
72,299
72,360
Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 5, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source
Showing the last 5 quarters. 22 more quarters, back to Mar 2020, with Tormere Pro.
What’s Going On With Biomea Fusion (BMEA) Stock After Hours? — Benzinga · 2026-10-14
Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss - Slideshow (NASDAQ:BMEA) 2026-10-14 — Seeking Alpha · 2026-10-14
Biomea Fusion’s BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study — Yahoo Finance · 2026-10-14
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist — Yahoo Finance · 2026-10-13
Tormere — informational purposes only, not investment advice.
